Spending and Utilization for Chronic Rhinosinusitis With Nasal Polyps Therapies Among Commercially Insured Beneficiaries.

The Food and Drug Administration (FDA) recently approved several novel therapies to treat chronic rhinosinusitis with nasal polyps (CRSwNP), though high prices may burden patients and payers. CRSwNP-specific spending varied widely by prescription drug among commercially insured patients, ranging from $7050 (EDS-FLU) to $28,324 (dupilumab). Condition-specific costs owed out-of-pocket ranged from $1036 (other drugs) to $3549 (mepolizumab).